Filing Flows

Filing Flows › Biolife Solutions (BLFS) › Q4 2025

Biolife Solutions (BLFS) Q4 2025 earnings results (fourth quarter 2025)

10-K filed Feb 26, 2026

Biolife Solutions (BLFS) reported revenue of $18.8M for the fourth quarter 2025 (Q4 2025), +24% from a year earlier and -33% from the quarter before. Operating margin was 7.2%, net earnings $11.1M (58.9% of revenue).

Revenue$18.8M
Year over year+24%
Quarter over quarter-33%
Operating margin7.2%
Net earnings$11.1M

Biolife Solutions, Q4 2025: revenue $18.8M (+24% year over year), operating margin 7.2%, net earnings $11.1M, operating cash flow $4.9M. The chart follows the revenue to costs, profit and cash.

Q4 2025AmountQ/QY/Y
Revenue$18.8M-33%+24%
Operating profit$1.3M—+149%
Net earnings$11.1M18×-11%
Operating cash flow$4.9M-19%+199%

What changed

Revenue was $18.8M in Q4 2025, up 24% year over year and down 33% from the previous quarter.

Operating profit was $1.3M, a 7.2% margin (up 3.6 points year over year). Of the extra revenue versus Q4 2024, 22% reached operating profit, above the 4% margin then. Total costs grew 20% against revenue growth of 24%. The fastest-growing cost line was Other operating costs (+246%). Net earnings were $11.1M, down 11% year over year. The effective tax rate was -1.6%. Non-operating items added $9.6M, 88% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was $4.9M (up 199% year over year), 44% of net earnings. Non-cash charges added back $261K of depreciation and amortization and $7.1M of share-based compensation. Working capital and other items used $13.5M.

Questions

What was Biolife Solutions' revenue in the fourth quarter 2025?

Biolife Solutions (BLFS) reported revenue of $18.8M for the fourth quarter 2025 (Q4 2025), +24% from a year earlier and -33% from the quarter before.

Was Biolife Solutions profitable in the fourth quarter 2025?

Operating profit was $1.3M (7.2% of revenue) and net earnings $11.1M.

Open the interactive Sankey →

Source: Biolife Solutions 10-K on SEC EDGAR.